Georgia's Online Cancer Information Center

Melanoma Clinical Trials in Georgia

**Clinical trials are research studies that involve people. These studies test new ways to prevent, detect, diagnose, or treat diseases. People who take part in cancer clinical trials have an opportunity to contribute to scientists’ knowledge about cancer and to help in the development of improved cancer treatments. They also receive state-of-the-art care from cancer experts... Click here to learn more about clinical trials.
Cancer Type = Melanoma
Cancer Type = Melanoma
There are currently 30 active Melanoma clinical trials in Georgia.
1.
A Beta-only IL-2 ImmunoTherapY (ABILITY) Study
Cancer Type
Bile Duct Cancer, Bladder Cancer, Cervical Cancer, Colon/Rectal Cancer, Gallbladder Cancer, Melanoma, Ovarian Cancer, Sarcoma, Stomach/ Gastric Cancer
NCT ID
NCT05086692
Protocol IDs
MDNA11-01
NCI-2022-02678
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
Scott Edelman
404-778-5180
2.
A FIH Study of PF-07284890 in Participants With BRAF V600 Mutant Solid Tumors With and Without Brain Involvement
Cancer Type
Lung Cancer, Melanoma
NCT ID
NCT04543188
Protocol IDs
C4471001
NCI-2020-08201
3.
A Multi-site, Prospective, Observational Study in US Patients with Advanced Melanoma
Cancer Type
Melanoma
NCT ID
Protocol IDs
CA184-199
IMPULSE
BMS CA184-199
5.
NCORP Trial
A Phase II/III Trial of Nivolumab, Ipilimumab, and GM-CSF in Patients with Advanced Melanoma
Cancer Type
Melanoma
NCT ID
NCT02339571
Protocol IDs
EA6141
NCI-2014-02674
Treatment Sites (5)
Augusta University Medical Center
Augusta
Carol Terry
706-721-4430
Northside Hospital Cancer Institute
Atlanta
Northside Hospital Central Research Department
404-303-3355
Winship Cancer Institute of Emory University
Atlanta
Scott Edelman
404-778-5180
6.
A Study of E7386 in Combination With Pembrolizumab in Previously Treated Participants With Selected Solid Tumors
Cancer Type
Colon/Rectal Cancer, Liver Cancer / Hepatoblastoma, Melanoma
NCT ID
NCT05091346
Protocol IDs
E7386-G000-201
NCI-2022-02226
2021-001568-10
KEYNOTE-C83
7.
A Study of Subcutaneous Nivolumab Monotherapy With or Without Recombinant Human Hyaluronidase PH20 (rHuPH20)
Cancer Type
Colon/Rectal Cancer, Liver Cancer / Hepatoblastoma, Melanoma
NCT ID
NCT03656718
Protocol IDs
CA209-8KX
NCI-2018-02324
2018-001585-42
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
Scott Edelman
404-778-5180
8.
A Study of TSR-022 in Participants With Advanced Solid Tumors (AMBER)
Cancer Type
Colon/Rectal Cancer, Lung Cancer, Melanoma
NCT ID
NCT02817633
Protocol IDs
4020-01-001
NCI-2016-01254
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
Scott Edelman
404-778-5180
9.
A Study to Assess Adjuvant Immunotherapy With Relatlimab and Nivolumab Versus Nivolumab Alone After Complete Resection of Stage III-IV Melanoma
Cancer Type
Melanoma, Unknown Primary
NCT ID
NCT05002569
Protocol IDs
CA224-098
NCI-2022-02119
2021-001641-13
10.
11.
Basket Study of Entrectinib (RXDX-101) for the Treatment of Patients With Solid Tumors Harboring NTRK 1/2/3 (Trk A/B/C), ROS1, or ALK Gene Rearrangements (Fusions)
Cancer Type
Bile Duct Cancer, Breast Cancer, Colon/Rectal Cancer, Head and Neck Cancer, Lung Cancer, Melanoma, Neuroendocrine Tumor, Ovarian Cancer, Pancreatic Cancer, Sarcoma
NCT ID
NCT02568267
Protocol IDs
RXDX-101-02
NCI-2015-01848
Treatment Sites (2)
Winship Cancer Institute of Emory University
Atlanta
Scott Edelman
404-778-5180
12.
Dose-Escalation and Dose-Expansion Study of ZX-4081 in Patients With Advanced Solid Tumors
Cancer Type
Breast Cancer, Colon/Rectal Cancer, Liver Cancer / Hepatoblastoma, Lung Cancer, Melanoma, Ovarian Cancer, Unknown Primary
NCT ID
NCT05118841
Protocol IDs
ZX-4081
NCI-2022-02249
13.
Duvelisib in Combination with Nivolumab for Treatment of Unresectable Stage IIIB-IV Melanoma
Cancer Type
Melanoma
NCT ID
NCT04688658
Protocol IDs
HCC 20-155
NCI-2021-13070
14.
KZR-261 in Subjects With Advanced Solid Malignancies
Cancer Type
Colon/Rectal Cancer, Eye Cancer, Melanoma, Mesothelioma, Prostate Cancer , Solid Tumor, Unknown Primary
NCT ID
NCT05047536
Protocol IDs
KZR-261-101
NCI-2022-01096
Treatment Sites (2)
Emory University Hospital - Midtown
Atlanta
Scott Edelman
404-686-4411
Winship Cancer Institute of Emory University
Atlanta
Scott Edelman
404-778-5180
15.
Melanoma Margins Trial-II: 1cm v 2cm Wide Surgical Excision Margins for AJCC Stage II Primary Cutaneous Melanoma
Cancer Type
Melanoma
NCT ID
NCT03860883
Protocol IDs
02.18
NCI-2019-07264
ANZMTG 02.18
16.
Oral STAT3 Inhibitor, TTI-101, in Patients With Advanced Cancers
Cancer Type
Breast Cancer, Colon/Rectal Cancer, Liver Cancer / Hepatoblastoma, Lung Cancer, Melanoma
NCT ID
NCT03195699
Protocol IDs
SM_CP2016-0842
NCI-2022-01107
17.
Perflutren Lipid Microspheres Ultrasound in Diagnosing Patients with Intraocular Tumors Undergoing Diagnostic Surgery
Cancer Type
Eye Cancer, Melanoma
NCT ID
NCT01930968
Protocol IDs
IRB0003943
Treatment Sites (1)
19.
Safety, PK and Efficacy of ONC-392 in Monotherapy and in Combination of Anti-PD-1 in Advanced Solid Tumors and NSCLC
Cancer Type
Breast Cancer, Colon/Rectal Cancer, Head and Neck Cancer, Liver Cancer / Hepatoblastoma, Lung Cancer, Melanoma, Ovarian Cancer, Pancreatic Cancer, Sarcoma, Stomach/ Gastric Cancer
NCT ID
NCT04140526
Protocol IDs
ONC-392-001
R44CA250824-01
NCI-2020-06149
20193108
4R44CA250824-02
21.
Study of ASP7517 Alone and With Pembrolizumab in Participants With Advanced Solid Tumors Expressing WT1 Antigen
Cancer Type
Colon/Rectal Cancer, Melanoma, Ovarian Cancer
NCT ID
NCT04837196
Protocol IDs
7517-CL-1101
NCI-2021-06479
22.
Study of INBRX-105 in Patients With Solid Tumors
Cancer Type
Lung Cancer, Melanoma
NCT ID
NCT03809624
Protocol IDs
Ph 1 INBRX-105
NCI-2019-02844
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
Scott Edelman
404-778-5180
23.
Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist)
Cancer Type
Lung Cancer, Melanoma, Stomach/ Gastric Cancer
NCT ID
NCT04198766
Protocol IDs
Ph 1 INBRX-106
NCI-2020-06313
MK3475 KEYNOTE A99
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
Scott Edelman
404-778-5180
24.
Study of ONCR-177 Alone and in Combination With PD-1 Blockade in Adult Subjects With Advanced and/or Refractory Cutaneous, Subcutaneous or Metastatic Nodal Solid Tumors or With Liver Metastases of Solid Tumors
Cancer Type
Breast Cancer, Colon/Rectal Cancer, Melanoma
NCT ID
NCT04348916
Protocol IDs
ONCR-177-101
NCI-2020-02978
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
Scott Edelman
404-778-5180
25.
Talimogene laherparepvec before Surgery for the Treatment of High-Risk and Treatment-Naive Recurrent Melanoma
Cancer Type
Melanoma
NCT ID
NCT04427306
Protocol IDs
CCSO034
NCI-2020-04098
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
Scott Edelman
404-778-5180
26.
NCORP Trial NCI Priority
Targeted Therapy Directed by Genetic Testing in Treating Patients with Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)
Cancer Type
Bladder Cancer, Brain & Spinal Cord Tumor, Breast Cancer, Cervical Cancer, Colon/Rectal Cancer, Esophogeal Cancer, Head and Neck Cancer, Kidney Cancer, Liver Cancer / Hepatoblastoma, Lung Cancer, Lymphoma, Melanoma, Multiple Myeloma, Ovarian Cancer, Pancreatic Cancer, Plasma cell neoplasm, Prostate Cancer , Skin Cancer (Non-Melanoma), Stomach/ Gastric Cancer, Thyroid Cancer, Unknown Primary, Uterine Cancer
NCT ID
NCT02465060
Protocol IDs
EAY131
NCI-2015-00054
EAY131-A
EAY131-B
EAY131-E
EAY131-F
EAY131-G
EAY131-H
EAY131-Q
EAY131-R
EAY131-U
EAY131-V
Treatment Sites (29)
Atlanta Cancer Care - Alpharetta
Alpharetta
Kristin Sieverding
770-777-1315
Atlanta Cancer Care - Conyers
Conyers
404-303-3355
Atlanta Cancer Care - Cumming
Cumming
Renee Gaiter
770-205-5292 x1041
Atlanta Cancer Care - Decatur
Decatur
404-303-3355
Atlanta Cancer Care - Stockbridge
Jonesboro
Andrena Jefferson
678 466-2069
Atlanta Cancer Care - Tower
Atlanta
404-303-3355
Atlanta Gynecologic Oncology
Atlanta
Jen Cuvo
404-303-3355
Atrium Health Navicent
Macon
Oncology Research Nurse
4786332152
Augusta University Medical Center
Augusta
Carol Terry
706-721-4430
Cancer Center at DeKalb Medical Center
Decatur
Cathy Comer
404-501-7789
Emory University Hospital - Midtown
Atlanta
Scott Edelman
404-686-4411
Georgia Cancer Specialists - Athens
Athens
Cynthia Pirkle
Georgia Cancer Specialists - CenterPointe
Sandy Springs
Anila Lokhandwala
404-256-4777 ext 9242
Georgia Cancer Specialists - Macon-Coliseum
Macon
Sonia Hernandez
478-745-6130 x8152
Georgia Cancer Specialists - Stemmer
Decatur
Nina Patel
770-496-5555
Harbin Clinic Cancer Center
Rome
Dilawar Khan, MD
706-528-9110
Northeast Georgia Medical Center - Gainesville
Gainesville
Trena Davis
770-219-8822
Northside Hospital Cancer Institute
Atlanta
Northside Hospital Central Research Department
404-303-3355
Pearlman Cancer Center at South Georgia Medical Center
Valdosta
Jeffrey Hoy
229-259-4628
University Gynecologic Oncology
Atlanta
Jen Cuvo
404-303-3355
Winship Cancer Institute of Emory University
Atlanta
Scott Edelman
404-778-5180
28.
Tipifarnib for the Treatment of Advanced Solid Tumors, Lymphoma, or Histiocytic Disorders with HRAS Gene Alterations, a Pediatric MATCH Treatment Trial
Cancer Type
Brain & Spinal Cord Tumor, Liver Cancer / Hepatoblastoma, Melanoma, Neuroblastoma, Non-Hodgkin Lymphoma, Sarcoma, Solid Tumor, Thyroid Cancer
NCT ID
NCT04284774
Protocol IDs
APEC1621M
APEC1621M
NCI-2020-01015
Treatment Sites (1)
Aflac Cancer and Blood Disorders Center of Children’s at Egleston
Atlanta
Howard M. Katzenstein, MD
404-785-0853
30.
VX15/2503 with or without Ipilimumab and/or Nivolumab in Treating Patients with Resectable Stage IIIB-D Melanoma
Cancer Type
Melanoma, Unknown Primary
NCT ID
NCT03769155
Protocol IDs
Winship4400-18
NCI-2018-01229
IRB00104273
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
Scott Edelman
404-778-5180
Georgia CORE

 

Advancing Cancer Care through Partnerships and Innovation

Georgia CORE is a statewide nonprofit that leverages partnerships and innovation to attract more clinical trials, increase research, and promote education and early detection to improve cancer care for Georgians in rural, urban, and suburban communities across the state.